"主动脉疾病死亡率，比很多癌症都更令人绝望，40%的患者没到医院就已离世，即便能够及时接受手术，欧美地区死亡率仍超17%。"香港中文大学医学院 外科学系教授、香港威尔斯亲王医院心胸外科主任黄鸿亮在接受记者采访时提及一组触目惊心的数据。 更棘手的是"漏诊魔咒"。由于主动脉疾病症状极具迷惑性，部分患者仅表现为腹痛、咳嗽、头晕，与普通感冒、肠胃炎等病症高度相似。黄鸿亮团队研究发 现，急诊室中30%的胸痛患者实际患有主动脉相关疾病，却因漏诊被当作普通病症处理，错过最佳治疗时机。"没有医生想漏诊，但主动脉疾病可能堵塞脑 部血管，症状复杂且隐蔽，再加上急诊室患者量大、诊疗时间紧张，漏诊几乎成了行业顽疾，引入AI超声诊断迫在眉睫。" 作为深耕心胸外科数十年的专家，黄鸿亮及其团队长期聚焦主动脉瘤、主动脉撕裂等高危疾病的诊疗难题，他见证了无数主动脉疾病患者与死神的博弈。他 认为，当下AI（人工智能）的飞速发展正成为这场"生死竞速"中的关键变量，也是他们破解"高死亡率、高漏诊率、诊疗资源错配"三大痛点的关键突破口。 日前，中国科学院香港创新研究院发布了其最新科研成果"聆音"EchoCare超声大模型。黄鸿亮在接受《每日经济新闻》 ...

每经记者｜甄素静 每经编辑｜魏官红 调研显示40%主动脉疾病患者未到医院便离世，30%患者在急诊中被漏诊 "主动脉就像城市里最繁忙的高速公路，负责将心脏血液输送到脑部、内脏等所有重要器官，一旦出问题，整个'交通系统'都会瘫痪。"黄鸿亮形象地比喻 道。主动脉最致命的问题，莫过于动脉瘤（血管壁膨胀形成"血肿瘤"）与主动脉撕裂，这两种情况一旦发生，短则几分钟、长则数小时，就能夺走患者生 命。 临床数据揭示了这场"生死战"的残酷。黄鸿亮团队通过长期研究发现，40%的主动脉撕裂患者在抵达医院前就因大出血或器官衰竭离世；即便顺利入院，等 待手术间隙，仍有患者因病情急转直下离世。即便是医疗水平领先的欧美国家，此类疾病的手术死亡率仍高达17%~20%，且术后有33%的患者需要再次接 受血管修复手术。 在香港地区，医疗资源分布情况加大了临床难度。黄鸿亮表示，香港公立医院中，仅3家医院具备开展主动脉疾病急诊手术的能力，其余医院若接收此类患 者，必须通过转院才能让患者获得有效救治。"从患者确诊到转院，每一分、每一秒都在消耗生存机会，很多患者没能撑到手术台。" "主动脉疾病死亡率，比很多癌症都更令人绝望，40%的患者没到医院就已离世 ...

Group 1 - Qilu Bank has established a comprehensive financial service ecosystem to support private enterprises, particularly in the marine economy sector, enhancing their operational capabilities and reducing financing barriers [1][2] - The bank has introduced innovative financial solutions, such as the "Blue Cold Chain Industry Chain Financial Solution," to address funding bottlenecks in the cold chain logistics industry, specifically for a leading enterprise in the region [2][3] - The cold storage utilization rate of the leading enterprise increased from 90% to 98%, and it became one of the busiest cold chain hubs in the Shandong Peninsula, with a daily throughput exceeding 800 tons [3] Group 2 - Qilu Bank has focused on technology finance, providing tailored financial products like "Kairong Loan" to support technology-driven enterprises, which have significant funding needs due to increased orders and R&D investments [4][5] - The bank has developed an online financing product called "Kairong e-loan," which evaluates the strength and potential of technology enterprises based on big data, effectively turning their technological capabilities into financial assets [5] - As of June, the balance of technology loans at Qilu Bank's Liaocheng branch reached 2.18 billion, reflecting a 30% increase since the beginning of the year [5] Group 3 - Qilu Bank has launched the "No Recourse Domestic Factoring (Quanshin Chain)" service to help small and micro enterprises manage their accounts receivable, providing them with efficient financing options [6][7] - The bank has successfully facilitated over 260 loans totaling more than 760 million for private enterprises through the "Quanshin Chain" product, addressing their accounts receivable financing challenges [7]

Core Insights - Yidu Technology (02158) announced that its subsidiary, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes to ultimately provide safer, higher-quality, and more accessible medical services [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, equipping doctors with precise and efficient decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and providing patients with affordable precision diagnosis and treatment [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

消息面上，复锐医疗科技公布，复锐(天津)与复星万邦(江苏)订立商业配送合作协议，该集团负责为产 品注射用A型肉毒毒素，内地商标为达希斐，于区域提供括商业化、市场推广、医学教育及商业计划服 务，于昨天至本年底及明年度的年度交易总额上限均为1700万美元。该集团指，该产品为一款由复星产 业再授权的产品，用于暂时性改善成人因皱眉肌及/或降眉间肌活动引起的中度至重度皱眉纹。该集团 指，订立商业配送合作协议获得额外收益。 复锐医疗科技(01696)涨超6%，截至发稿，涨6.41%，报5.98港元，成交额1097.52万港元。 ...

Core Viewpoint - The company, Jianerkang Medical Technology Co., Ltd., is set to hold a half-year performance briefing on October 10, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3][4]. Group 1: Meeting Details - The performance briefing will take place on October 10, 2025, from 11:00 AM to 12:00 PM [2][4]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3]. - Investors can submit questions from September 25, 2025, to October 9, 2025, before 4:00 PM, through the Roadshow Center website or via the company's email [2][5]. Group 2: Company Representatives - The meeting will feature key company representatives, including Chairman and General Manager Chen Guoping, Board Secretary Liu Ping, and Chief Financial Officer Gong Xiaole [4][5]. - Adjustments to the attending personnel may occur due to special circumstances [4]. Group 3: Post-Meeting Information - After the briefing, investors can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [5].

Core Viewpoint - Hangzhou Bank is committed to serving the real economy and has successfully launched the "Zheke United Loan," a new financing model for technology enterprises, reflecting its long-term efforts in building a specialized technology financial service system [1] Group 1: Overview of "Zheke United Loan" - "Zheke United Loan" is guided by multiple financial and governmental bodies, aiming to address the financing challenges faced by technology enterprises throughout their lifecycle [2] - The loan program includes three sub-products: "Inclusive United Loan," "Growth United Loan," and "Leading United Loan," tailored to meet the diverse financial needs of technology enterprises at different stages [2] Group 2: Focus on Inclusive Financing - The program emphasizes inclusive finance, targeting small and micro technology enterprises that require assistance [3] - A joint service team was established between Hangzhou Bank and Industrial and Commercial Bank of China to provide tailored support to high-growth technology enterprises [3] Group 3: Growth Financing Solutions - The "Growth United Loan" has been customized for a startup medical enterprise, providing a credit line of 12 million yuan with a loan rate 26 basis points lower than the average [5] - This support has enabled the enterprise to meet its funding needs for research, production, and expansion [5] Group 4: Large Demand Financing - The "Leading United Loan" is designed for mature technology enterprises with significant funding needs, offering high credit limits and long terms [6] - A collaboration with Minsheng Bank has facilitated a project that supports a digital healthcare enterprise, enhancing its capacity for innovation and service quality [6] - The program integrates various resources to provide stable and diverse financial support for technology enterprises throughout their growth lifecycle [6]

Group 1 - The core viewpoint of the news is that Furuya Co., Ltd. experienced a decline in stock price by 5.01%, with a current share price of 81.50 yuan and a total market capitalization of 21.596 billion yuan [1] - Furuya Co., Ltd. is primarily engaged in the production and sales of pharmaceuticals related to liver diseases, as well as the research and sales of medical instruments and medical services [1] - The company's revenue composition is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1] Group 2 - Among the top ten circulating shareholders of Furuya Co., Ltd., a fund under Ruiyuan Fund holds a significant position, having reduced its holdings by 1.283 million shares in the second quarter [2] - Ruiyuan Growth Value Mixed A (007119) currently holds 5.5666 million shares, accounting for 2.38% of the circulating shares, with an estimated floating loss of approximately 23.9362 million yuan [2] - The fund has achieved a year-to-date return of 61.45% and a one-year return of 90.34%, ranking 498 out of 8172 and 831 out of 7980 respectively [2]

（原标题：软通动力新设信息技术公司；欧森斯启动智慧渔业计划丨横琴财报?） 近日，由珠海欧森斯传感技术有限公司（简称：欧森斯）牵头的海鲈鱼智慧喂养实验正式启动。该项目通过物联网、人工智能与大数据等现代科 技手段，通过智能传感、AI决策与自动化控制等技术，全面提升白蕉海鲈养殖的精准化、智能化水平，不仅助力渔民降本增效，更致力于推动渔 业生产方式的变革。针对此次白蕉海鲈智慧养殖实验，欧森斯全新推出的智慧养殖信息系统同步投入使用。 该系统作为本次实验的"数据大脑"，可实现对实验塘区的集中化、数字化和智能化管理。其中，单塘管理可实时监测鱼类进食活跃度、水温、溶 氧、PH值及ORP等多维水质数据，支持用药记录、鱼规格跟踪，并依托设定计划自动调整投喂策略。系统具备多级权限管理与异常报警功能，并 集成视频监控，保障养殖安全。多塘管理模块提供全局数据汇总与对比分析，助力养殖者高效决策，提升生产效益。 欧森斯成立于2015年，位于横琴粤澳深度合作区，是广东省专精特新中小企业。公司专注于消费电子、半导体封装测试、锂电及农业检测等领域 的高端测试设备研发、制造与解决方案提供。其自主开发的多功能集成板卡、高速芯片测试分选设备等核心产品 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 招商招财通理财债券型证券投资基金（以下简称"本基金"）基金合同于2017年6月19日正式生效。本基 金的第十五个封闭期为自2025年6月13日（含）至2025年9月15日（含）止，共计95天。本基金A类份额 （基金代码：004667）在第十五封闭期的实际收益率（净值增长）为0.31%。本基金C类份额（基金代 码：005471）在第十五个封闭期实际无份额存续。 本公告仅对本基金第十五个封闭期实际收益率的有关事项予以说明。投资者欲了解本基金的详细情况， 请阅读本基金的基金合同、招募说明书等，以及2025年6月10日刊登在《中国证券报》和本基金管理人 网站（www.cmfchina.com）上的《关于招商招财通理财债券型证券投资基金第十五个开放期办理申购 赎回及转换业务和第十五个封闭期相关安排的公告》，或拨打本基金管理人的客户服务中心电话（400- 887-9555）进行查询。 风险提示： ■ 如有疑问，请拨打客户服务热线：400-887-9555，或登录网站www.cmfchina.com 获取相关信息。 风险提示：本公司承诺以诚实信用、勤勉尽责的原则管理和运用基 ...